Clinical Trial Search

Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 1 participants

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 1; 2; 1; 3 Participants

Primary: Apnea-Hypopnea Index — 11.5; 11.5; 18.8 events/hour — p=<0.0001

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 1; 0; 3 Participants

Primary: Mean Glomerular Filtration Rate by Iohexol Clearance at Week 52 — 37.0; 40.1 mL/min/1.73 m²

Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants

Primary: Changes in the Mean Daily Numerical Rating Scale (NRS) Scores for the Worst Endometriosis-related Pain. — -0.66; -2.04; -2.14; -3.68 score on a scale

Primary: Biphasic Alcohol Effects Scale (BAES): Stimulant Subscale — 13.756; 14.053; 13.026 score on a scale — p=0.867

Primary: Response to Treatment by RECIST Criteria — 3; 3; 48; 47 Participants

Primary: Number of Participants With ≥ 5% Reduction in Body Weight From Baseline After 3 Months of Setmelanotide Treatment — 6; 3; 7; 7 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 9; 0 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 7; 7; 5 Participants

Primary: Incidence of Adverse Events — 13; 11; 15 Participants

Primary: Achievement of EASI-50 — 38; 27; 25; 23 Participants

Primary: Change From Baseline in Peripheral Eosinophil Count at Day 22 — -0.199; -0.141 10^9 cells/Liters — p=0.5703